A major obstacle interfering with the success of cell and gene-based therapies is the response of the immune system. Greffex developed a novel adenoviral vector system successfully to address this issue. Safety concerns over viral materials present in gene therapy vectors used in the treatment of human diseases were a key driver in the development of a new delivery vector for Greffex’s therapies.

Our enabling technology utilizes the only patented fully-deleted, helper-independent adenoviral vector, which we believe is the final adenoviral vector. This innovation overcomes the risk of viral materials when used in cell- and gene-based therapies. It also allows the creation of a more effective and efficient transfer vehicle, transforming cells and tissues into specifically immune-suppressive moieties (transplantation) and accommodating larger payloads (gene therapy).